Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
The cannabinoid delta-9-tetrahydrocannabinol is the principal psychoactive ingredient of marijuana. The proteins encoded by this gene and the cannabinoid receptor 1 (brain) (CNR1) gene have the characteristics of a guanine nucleotide-binding protein (G-protein)-coupled receptor for cannabinoids. They inhibit adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner. These proteins have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. The cannabinoid receptors are members of family 1 of the G-protein-coupled receptors.
|Gene Name:||cannabinoid receptor 2 (macrophage)|
|Family/Subfamily:||GPCR , Cannabinoid|
|Synonyms:||CNR2, Cannabinoid receptor 2, CB2, CB2 cannabinoid receptor, CX5, CB2R, HCB2, Cannabinoid CB2 receptor, CB-2, CB2 receptor|
|Target Sequences:||NM_001841 NP_001832.1 P34972|
If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.